Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other financing activities: 2009-2024

Historic Other financing activities for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $23,000.

  • Lineage Cell Therapeutics' Other financing activities fell 34.78% to $15,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $1.1 million, marking a year-over-year decrease of 52.49%. This contributed to the annual value of $23,000 for FY2024, which is 37.84% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Other financing activities stood at $23,000 for FY2024, which was down 37.84% from $37,000 recorded in FY2023.
  • Lineage Cell Therapeutics' Other financing activities' 5-year high stood at $3.5 million during FY2021, with a 5-year trough of $23,000 in FY2024.
  • Moreover, its 3-year median value for Other financing activities was $37,000 (2023), whereas its average is $55,333.
  • Its Other financing activities has fluctuated over the past 5 years, first spiked by 58.02% in 2021, then slumped by 96.99% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Other financing activities (Yearly) stood at $2.2 million in 2020, then soared by 58.02% to $3.5 million in 2021, then crashed by 96.99% to $106,000 in 2022, then slumped by 65.09% to $37,000 in 2023, then crashed by 37.84% to $23,000 in 2024.